Edition:
United States

Zai Lab Ltd (ZLAB.OQ)

ZLAB.OQ on NASDAQ Stock Exchange Global Market

29.46USD
4:00pm EDT
Change (% chg)

$0.08 (+0.27%)
Prev Close
$29.38
Open
$29.35
Day's High
$30.18
Day's Low
$29.19
Volume
47,037
Avg. Vol
52,736
52-wk High
$33.85
52-wk Low
$14.29

Latest Key Developments (Source: Significant Developments)

Zai Lab Ltd Files For Offering Of Ordinary Shares In Form Of Ordinary Shares Or ADSs, Size Undisclosed
Friday, 29 Mar 2019 06:33pm EDT 

March 29 (Reuters) - Zai Lab Ltd ::ZAI LAB LTD FILES FOR OFFERING OF ORDINARY SHARES IN FORM OF ORDINARY SHARES OR AMERICAN DEPOSITARY SHARES, SIZE NOT DISCLOSED - SEC FILING.  Full Article

Macrogenics And Zai Lab Announce Agreement To Develop And Commercialize Margetuximab, MGD013 And TRIDENT Molecule In Greater China
Thursday, 29 Nov 2018 07:30am EST 

Nov 29 (Reuters) - MacroGenics Inc ::MACROGENICS AND ZAI LAB ANNOUNCE EXCLUSIVE COLLABORATION AND LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE MARGETUXIMAB, MGD013 AND TRIDENT™ MOLECULE IN GREATER CHINA.MACROGENICS INC - MACROGENICS TO RECEIVE $25 MILLION UPFRONT CASH PAYMENT AND POTENTIAL FUTURE MILESTONES AND ROYALTIES.MACROGENICS INC - MACROGENICS WILL BE ELIGIBLE TO RECEIVE UP TO $140 MILLION IN POTENTIAL DEVELOPMENT AND REGULATORY-BASED MILESTONE PAYMENTS.MACROGENICS INC - ZAI LAB WOULD PAY MACROGENICS DOUBLE-DIGIT ROYALTIES ON ANNUAL NET SALES OF ASSETS.  Full Article

Zai Lab Appoints Tao Fu As President & COO
Thursday, 27 Sep 2018 07:30am EDT 

Sept 27 (Reuters) - Zai Lab Ltd ::ZAI LAB APPOINTS INDUSTRY LEADER TAO FU AS PRESIDENT & CHIEF OPERATING OFFICER, EXPANDS US PRESENCE.ZAI LAB LTD - ANNOUNCED APPOINTMENT OF TAO FU AS PRESIDENT AND CHIEF OPERATING OFFICER, EFFECTIVE SEPT 24, 2018.  Full Article

Novocure And Zai Lab Announce Strategic Collaboration
Wednesday, 12 Sep 2018 07:30am EDT 

Sept 12 (Reuters) - Zai Lab Ltd ::NOVOCURE AND ZAI LAB ANNOUNCE STRATEGIC COLLABORATION WITH A LICENSE AGREEMENT FOR TUMOR TREATING FIELDS IN GREATER CHINA.ZAI LAB LTD - ZAI LAB WILL SUPPORT ENROLLMENT OF CHINESE PATIENTS TO CERTAIN CLINICAL TRIALS INVESTIGATING TUMOR TREATING FIELDS.ZAI LAB LTD - NOVOCURE WILL RECEIVE A $15 MILLION UPFRONT PAYMENT.ZAI LAB LTD - NOVOCURE IS ALSO ELIGIBLE TO RECEIVE ADDITIONAL PAYMENTS UPON ACHIEVEMENT OF CERTAIN DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONES.ZAI LAB LTD - NOVOCURE GRANTED ZAI LAB AN EXCLUSIVE LICENSE TO COMMERCIALIZE TUMOR TREATING FIELDS IN CHINA, HONG KONG, MACAU AND TAIWAN.ZAI LAB LTD - ZAI LAB WILL BE RESPONSIBLE FOR REGULATORY SUBMISSIONS IN GREATER CHINA.  Full Article

Zai Lab Files For Offering ADSs For A Total Price To Public Of $150 Mln
Friday, 31 Aug 2018 04:33pm EDT 

Aug 31 (Reuters) - Zai Lab Ltd ::ZAI LAB LTD FILES FOR OFFERING ADSS FOR A TOTAL PRICE TO PUBLIC OF $150 MILLION - SEC FILING.ZAI LAB LTD SAYS J.P. MORGAN, CITIGROUP, JEFFERIES & LEERINK PARTNERS ARE AMONG UNDERWRITERS FOR OFFERING.  Full Article

Five Prime Therapeutics And Zai Lab Announce Exclusive License Agreement
Tuesday, 19 Dec 2017 04:05pm EST 

Dec 19 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS AND ZAI LAB ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR FPA144 ANTI-FGFR2B ANTIBODY IN GREATER CHINA AND GLOBAL STRATEGIC DEVELOPMENT COLLABORATION.FIVE PRIME THERAPEUTICS - GRANTED ZAI LAB AN EXCLUSIVE LICENSE TO DEVELOP AND COMMERCIALIZE FPA144 IN GREATER CHINA TERRITORY​.FIVE PRIME THERAPEUTICS INC - ‍ZAI LAB WILL BE RESPONSIBLE FOR CONDUCTING PHASE 3 FIGHT TRIAL IN GREATER CHINA​.  Full Article